Biotech stocks took a tumble on Monday with the XBI S&P biotech ETF and IBB Nasdaq biotech ETF each falling by more than 1 percent.
"If you're playing biotech, you're counting on little companies doing something amazing and hopefully getting bought by a big company," Nadig said on CNBC's"ETF Edge" on Monday."We saw that in the last couple of weeks when Spark Therapeutics got bought by Roche, that was a significant position in XBI. It's barely in IBB."
To Ben Johnson, director of global ETF research at Morningstar, the equal-weighted XBI ETF offers big returns, but volatility in the biotech segment means investors need to have a strong stomach.
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
Watch now: ETF Edge on the market sell-off, and the Tesla-heavy ETF that's beating the S&P this year
더 많은 것을 읽으십시오 »
Biotech stocks are going wild, and these two could be your best bet for a bigger breakoutBiotech is blazing higher. One technician says it should continue to be a healthy trade.
더 많은 것을 읽으십시오 »